戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Anti-idiotype 3H1 mimics a distinct and specific epitope
2 ived mature dendritic cells (DC) loaded with anti-idiotype 3H1 or CEA could reverse CEA unresponsiven
3                   Here, we have combined the anti-idiotype 3H1 with the CTL peptides of CEA to augmen
4 e sera from 40 of 47 patients showed an anti-anti-idiotype (Ab3) response.
5                                              Anti-idiotype (anti-Id) antibody can induce tumor dorman
6             We developed a murine monoclonal anti-idiotype (anti-Id) antibody, 3H1, which mimics a sp
7                               Tumor-specific anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to
8                 Here, we produced a panel of anti-idiotype antibodies able to specifically recognize
9 proach that is analogous to the isolation of anti-idiotype antibodies and were able to isolate peptid
10 assay (ELISA) assays for idiotype protein or anti-idiotype antibodies in serum.
11                                              Anti-idiotype antibodies, in addition to cytotoxic T cel
12 al inactive disease in patients treated with anti-idiotype antibodies.
13  were treated with 52 courses of custom-made anti-idiotype antibodies.
14  characterize the structural footprint of an anti-idiotype antibody (E1) specific for a potent, fully
15 dendritic cells (DCs) pulsed with the murine anti-idiotype antibody 3H1 as a tumor vaccine.
16 s studies suggested that vaccination with an anti-idiotype antibody 3H1, which mimics a specific epit
17 se unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that ea
18                 This material reacts with an anti-idiotype antibody by Western blotting, ELISA, and a
19                           The C3d-conjugated anti-idiotype antibody induces a strong idiotype and ant
20                        We have reported that anti-idiotype antibody response and FcgammaRIIIa 158 val
21 data demonstrate the utility of employing an anti-idiotype antibody to monitor a patient's specific i
22 ound to inhibit mAb HGAC 39.G3 binding to an anti-idiotype antibody with approximately 1000-fold grea
23 rcinoembryonic antigen (CEA), and that of an anti-idiotype antibody, 3H1, which mimics CEA and can be
24                              We generated an anti-idiotype antibody, designated CeaVac, that is an in
25 at binds the same protein and is superior to anti-idiotype approaches.
26                   Here, we developed a novel anti-idiotype aptamer (termed A14#1) with extraordinary
27 ve demonstrated the general applicability of anti-idiotype aptamers as capture reagents in quantifica
28             Together, our data indicate that anti-idiotypes are a valuable tool for the study and ind
29 , day 112, and day 168) were assessed via an anti-idiotype binding assay and characterised via non-co
30 nhibitor protein (BLA-BLIP) complex with two anti-idiotype binding proteins (Affimer proteins) as rec
31 ntibody elicits an anti-antibody response or anti-idiotype, consequently producing a disease-inciting
32 l as the use of photopheresis to generate an anti-idiotype cytotoxic T-cell response.
33 minidase, and three Fab complexes with their anti-idiotype Fabs.
34 phoma based on tumor idiotype (Id) has shown anti-idiotype humoral immune responses in 40%-50% and ce
35                          We propose that the anti-idiotype (Id) binds to rituximab molecules bound un
36 jor histocompatibility complex (MHC) II, and anti-idiotype (Id) radiolabeled with 131-iodine.
37 a of multiple donors resulting from idiotype/anti-idiotype (Id/anti-Id) interactions.
38 rall survival of all 20 patients mounting an anti-idiotype immune response are significantly prolonge
39 eeded to prove a causal relationship between anti-idiotype immunity and improved clinical outcome.
40 rified 38C13 scFv generate >10 micrograms/ml anti-idiotype immunoglobulins.
41   We determined the crystal structure of two anti-idiotypes in complex with iglb12 and used these ant
42 nization with a multimerized version of this anti-idiotype induced the proliferation of transgenic mu
43 PNAG bound together via an apparent idiotype-anti-idiotype interaction.
44 cluding the case previously studied using an anti-idiotype, involvement of the splenic marginal zone
45 with the experimental fact that the level of anti-idiotypes is low in autoimmune patients but high in
46   mAb GH1002 was elicited with the syngeneic anti-idiotype mAb MK2-23 which mimics the determinant de
47 cular adjuvant peptide is crosslinked to the anti-idiotype mimetic by chemical means without modifyin
48             We isolated and characterized an anti-idiotype monoclonal antibody 3H1, which mimics a di
49 vizumab as a synthetic cytokine and a set of anti-idiotype nanobodies (AIP(VHH)) as synthetic recepto
50 d anti-idiotype vaccines and identified that anti-idiotype nanobodies could mimic the antigen on amin
51 bs against different pathogens are prepared, anti-idiotype nanobody vaccines can be easily produced a
52 TANCEAnti-idiotype vaccines utilize idiotype-anti-idiotype network theory, eliminating the need for e
53                                              Anti-idiotype of (natural) autoantibodies participate in
54                      Focusing on an idiotype/anti-idiotype pair embedded in an environment such as th
55 he first detailed molecular comparison of an anti-idiotype paratope specific for a human antibody wit
56 demonstrate that the resultant semisynthetic anti-idiotype peptibodies kill tumor cells in vitro with
57  hybridoma-generated vaccines, we found that anti-idiotype production was even more highly associated
58 olipin antibodies (the latter by an idiotype-anti-idiotype reaction).
59 mmunity through a network involving idiotype-anti-idiotype reactions termed 'autoantigen complementar
60                                     Although anti-idiotype responses are theoretically possible again
61 reatment with CAMPATH-1H can lead to patient anti-idiotype responses which may be exacerbated by the
62 en subcutaneous alemtuzumab made substantial anti-idiotype responses.
63 st detailed molecular comparison between the anti-idiotype surface and its analogous epitope located
64       The idea is to introduce an antigen or anti-idiotype that binds to the autoantibodies with high
65 ft, the bystander effect, molecular mimicry, anti-idiotype theory, antigenic complementarity, and dua
66 otypes in complex with iglb12 and used these anti-idiotypes to identify rare naive human B cells expr
67                      It highlighted that the anti-idiotype vaccine using nanobody has a very good app
68          To enhance the immunogenicity of an anti-idiotype vaccine we incorporated a molecular adjuva
69 ided a strategy for producing nanobody-based anti-idiotype vaccines and identified that anti-idiotype
70                                              Anti-idiotype vaccines are safer due to their absence of
71 er, the commercial production of traditional anti-idiotype vaccines using monoclonal and polyclonal a
72 el, simple, low-cost strategy for developing anti-idiotype vaccines with nanobody technology.
73 sal, simple, low-cost strategy for producing anti-idiotype vaccines with nanobody technology.
74                          However, developing anti-idiotype vaccines with traditional monoclonal and p